1 min read|41 words
Rb pathway inactivation emerges as the consistent molecular feature driving squamous transformation in EGFR-mutant lung cancers—a finding that could enable earlier intervention and prevent treatment resistance. New research in Science Translational Medicine (June 2026).
Read the full article on GMJ Newsroom →
Was this article helpful?

